[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"siewert-type-ii-adenocarcinoma-of-esophagogastric-junction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:siewert-type-ii-adenocarcinoma-of-esophagogastric-junction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100626911","immediate-and-functional-results-of-different-types-of-reconstructions-after-proximal-gastrectomy-for-gastric-and-esophagogastric-junction-cancer-100626911",false,"NCT07441785","Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer","PROXISTAT","Inclusion Criteria:\n\n* All consecutive patients with clinically documented primary Gastric or Esophagogastric Junction malignancy (including Siewert I and II) cT1-3N0-2M0 undergoing proximal gastrectomy with curative intent - via open, laparoscopic or robotic approach between 01th January 2025 and 31th December 2026\n\nExclusion Criteria:\n\n* Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers.\n* Esophagogastric Junction Siewert I malignancy\n* Patients submitted to Emergency surgery or surgery without curative intent\n* Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy\n* Patients who have previously undergone surgery on the stomach or colon","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues.\n\nRising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques).\n\nEach method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL.\n\nNo consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied.\n\nSystematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.",[24,25,26],"Gastric Cancer (GC)","Siewert Type III Adenocarcinoma of Esophagogastric Junction","Siewert Type II Adenocarcinoma of Esophagogastric Junction",[28,29,30,31,32,33],"Proximal gastrectomy","Morbidity","Mortality","Quality of life","Surgery","Esophagogastric Junction Cancer","RECRUITING","2026-04-17",{"date":37,"type":38},"2026-04-22","ACTUAL",{"date":40,"type":38},"2025-01-01",{"date":42,"type":20},"2029-06-01",{"name":44,"class":45},"P. Herzen Moscow Oncology Research Institute","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100466652","comparison-of-different-operations-for-siewert-type-ii-adenocarcinoma-of-esophagogastric-junction-100466652","NCT05356520","Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction","A Multicenter Randomized Controlled Study of Siewert II Esophagogastric Junction Adenocarcinoma With Endoscopic Ivor-Lewis Approach Versus Laparoscopic Transabdominal Extended Gastrectomy","Inclusion Criteria:\n\n* Histologically confirmed EGJ type II adenocarcinoma\n\n  ··The tumor can be removed by laparoscopy through the gastrodiaphragmatic esophageal hiatus or by endoscopic Ivor Lewis operation\n* Pretreatment stage CT1-4A, N0-3, M0\n* For cT4a stage patients, their resectable properties must be clearly verified before randomization\n* For locally advanced tumors (CT3-T4 or N+), all 4 cycles of chemotherapy (FLOT) were completed before surgery.\n* 18 to 75 years old\n* ECOG score 0-2\n* ASA \\\u003C4\n* Good bone marrow function (leukocyte \\> x 10 \\^ 9 \u002F l; Hemoglobin\\> 9 g\u002Fdl. ·Platelet\\>100×10\\^9\u002F L), renal function (glomerular filtration rate \\& GT; 60ml\u002Fmin) and liver function (total bilirubin \\< 1.5 times normal (ULN), aspartate aminotransferase (AST\\\u003C 2.5x ULN, Alanine aminotransferase (ALT)\\\u003C3 x ULN)\n* Patients and their family members voluntarily sign written informed consent\n\nExclusion Criteria:\n\n* Histologically confirmed EGJ type I and III adenocarcinoma\n* Tumor spread over 5 cm proximal to EGJ\n* Clinically significant (active) heart disease (i.e. symptomatic coronary artery disease or myocardial infarction within the last 12 months) resulting in left ventricular ejection fraction\\\u003C50%(determined by echocardiography)\n* Clinically significant lung diseases (forced expiratory volume in 1 second (FEV1)\\\u003C1.5 l\u002Fs)\n* Pregnant women and nursing mothers\n* Stump gastric cancer\n* Borrmann Type 4 (Leather stomach)\n* Simultaneous or heterochronous malignant tumors of other organs except carcinoma in situ of the cervix and adenoma and focal colorectal carcinoma\n* Right thoracotomy or history of right pleural adhesion\n* Cirrhosis, or indocyanine green test ≥15% of chronic liver disease\n* No seizure control, central nervous system diseases or mental disorders\n* History of upper abdominal surgery (except laparoscopic cholecystectomy)\n* The patient has coagulation dysfunction and cannot be corrected\n* Patients with heart, lung, liver, brain, kidney and other important organ failure\n* Patients with metabolic diseases such as diabetes\n* Immunosuppressive therapy, such as organ transplantation, SLE, etc\n* Seriously out of control recurrent infections or other seriously out of control concomitant diseases\n* Other diseases requiring simultaneous surgery\n* Diseases requiring emergency surgery due to tumor emergencies (e.g. hemorrhage, perforation, obstruction)","75 Years",{"count":56,"type":20},212,"INTERVENTIONAL",[59],"NA","The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.",[26],"2024-11-06",{"date":64,"type":38},"2024-11-08",{"date":66,"type":38},"2022-05-01",{"date":68,"type":20},"2028-05-31",{"name":70,"class":71},"Xijing Hospital of Digestive Diseases","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":57,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100565605","right-versus-left-thoracic-surgical-approaches-for-siewert-ii-gastroesophageal-junction-adenocarcinoma-100565605","NCT06644352","Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma","A Prospective, Randomized, Controlled, Multicenter Study Comparing the Right Versus Left Thoracic Surgical Approaches for Locally Advanced Siewert II Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n1. Histologically confirmed gastroesophageal adenocarcinoma;\n2. R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification);\n3. Have a performance status of 0 or 1 on the ECOG Performance Scale;\n4. Age 18-80 years old, both men and women;\n5. Estimated survival ≥6 months;\n6. Be willing and able to provide written informed consent\u002Fassent for the trial;\n7. Demonstrate adequate organ function ;\n8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days before enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;\n9. Have not received systemic or local treatment for esophageal cancer in the past.\n\nExclusion Criteria:\n\n1. Have a history of other malignant tumors in the past or at the same time;\n2. Previous upper abdominal surgery (excluding cholecystectomy);\n3. Bleeding, perforation and obstruction requiring emergency surgical treatment;\n4. Severe heart, lung, liver and kidney dysfunction, which the researcher thinks is not suitable for operation;\n5. Hydrothorax and ascites with clinical symptoms need therapeutic puncture or drainage;\n6. Participate in other clinical studies or less than 1 month from the end of the previous clinical study;\n7. Have a history of psychoactive drug abuse, alcoholism or drug abuse;\n8. Be unable or do not agree to bear the inspection and treatment expenses at their own expense;\n9. The researcher thinks that it should be excluded from this study.","80 Years",{"count":81,"type":20},236,[59],"To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy",[26],[86,87,88,89,90],"GastroEsophageal Cancer","Surgical Incision","Left thoracic incision","Right thoracic incision","Neoadjuvant chemotherapy","2024-10-14",{"date":93,"type":38},"2024-10-16",{"date":95,"type":38},"2022-07-01",{"date":97,"type":20},"2027-07-01",{"name":99,"class":71},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]